25 results on '"Kwak, Larry W."'
Search Results
2. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
3. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
4. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
5. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
6. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
7. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
8. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach
9. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
10. Double hit lymphoma: the MD Anderson Cancer Center clinical experience
11. Induction of p53‐mediated transcription and apoptosis by exportin‐1 ( XPO 1) inhibition in mantle cell lymphoma
12. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma
13. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
14. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma
15. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production
16. Targeting cell surface β2-microglobulin by pentameric IgM antibodies
17. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma
18. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
19. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
20. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma
21. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry
22. Models for Lymphoma
23. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions
24. MACOP-B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices
25. Clinical significance of morphologic subdivision in diffuse large cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.